Who
William F. Doyle
Director
Company insider
Files Form 4 as: Director, ProKidney; Executive Chairman, NovoCure; Director, Elanco Animal Health; Director, Minerva Neurosciences; Director and 10% owner, OptiNose.
In numbers
- Trades disclosed
- 161
- Buys
- 13
- Sells
- 27
- Bought
- $722K
- Sold
- $74.2M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 3 Jan 2017
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —200,284 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $646K50,557 at $12.79 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,445 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,072 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $286K21,330 at $13.43 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —258,445 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,072 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —200,284 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $647K50,557 at $12.79 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $286K21,330 at $13.43 | filing |
| 29 May 2025filed 2 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,862 at $0.00 | filing |
| 29 Nov 2024filed 3 Dec 2024 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —18,169 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,558 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Bought | $255K15,000 at $16.98 | filing |
| 8 Mar 2024filed 12 Mar 2024 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Bought | $245K15,000 at $16.30 | filing |
| 30 Nov 2023filed 4 Dec 2023 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —20,374 at $0.00 | filing |
News
Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)NVCR · tickerreport.com · 15 Oct 2026NovoCure (NASDAQ:NVCR) and Medline (NASDAQ:MDLN) Financial AnalysisNVCR · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name William F. Doyle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.